Literature DB >> 1279269

Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes.

J Floege1, C E Alpers, E H Sage, P Pritzl, K Gordon, R J Johnson, W G Couser.   

Abstract

BACKGROUND: Visceral glomerular epithelial cells (GEC) are an important component of the glomerular filtration barrier to proteins. While ultrastructural GEC changes have frequently been observed in proteinuric states, no suitable light microscopic markers of GEC injury have yet been identified. EXPERIMENTAL
DESIGN: We have analyzed in vivo the GEC expression of proteins known to be involved in cell shape changes. SPARC (osteonectin, BM-40) and tenascin (cytotactin, J1, hexabrachion) belong to a group of anti-adhesive glycoproteins, that modulate cell-matrix interactions. We also studied cytoskeletal intermediate filament proteins, including desmin and vimentin. The GEC expression of SPARC, tenascin, desmin, and vimentin was analyzed in various types of GEC injury in the rat, including complement-mediated injury (passive Heymann nephritis, autologous immune complex nephritis, conA anti-conA nephritis), complement-independent injury (nephrotoxic nephritis), toxic injury (aminonucleoside nephrosis) and hypertensive injury (5/6 nephrectomy, angiotensin-II infusion). A complement-mediated model of mesangial cell injury (anti-Thy 1.1 mesangial proliferative nephritis) served as a control.
RESULTS: SPARC mRNA and protein were constitutively expressed in normal rat glomeruli. Immunostaining and immunoelectron microscopy primarily localized SPARC to the cytoplasm of GEC. Markedly increased glomerular SPARC synthesis and GEC immunostaining was observed in all instances of complement-mediated GEC injury but in none of the other conditions. In contrast, glomerular immunostaining for tenascin, that also stained in a GEC pattern, either remained unchanged or increased to a minor degree (complement-mediated models). GEC immunostaining for desmin in normal rats was low and variable, and increased significantly in any form of GEC injury but not in anti-Thy 1.1 nephritis. No concomitant increase of GEC immunostaining for vimentin was detectable, which could have been due to the constitutively high expression of vimentin in GEC.
CONCLUSIONS: SPARC and desmin, but not tenascin or vimentin, are suitable light microscopic markers of GEC injury. The combined staining for these proteins may be useful in differentiating the mechanisms of GEC injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279269

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  25 in total

1.  Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.

Authors:  Mauro Abbate; Carla Zoja; Marina Morigi; Daniela Rottoli; Stefania Angioletti; Susanna Tomasoni; Cristina Zanchi; Lorena Longaretti; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Gene expression in the normal adult human kidney assessed by complementary DNA microarray.

Authors:  John P T Higgins; Lingli Wang; Neeraja Kambham; Kelli Montgomery; Veronica Mason; Stefanie U Vogelmann; Kevin V Lemley; Patrick O Brown; James D Brooks; Matt van de Rijn
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

3.  Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis.

Authors:  S Breiteneder-Geleff; K Matsui; A Soleiman; P Meraner; H Poczewski; R Kalt; G Schaffner; D Kerjaschki
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  Subtotal ablation of parietal epithelial cells induces crescent formation.

Authors:  Eva-Maria Sicking; Astrid Fuss; Sandra Uhlig; Peggy Jirak; Henry Dijkman; Jack Wetzels; Daniel R Engel; Torsten Urzynicok; Stefan Heidenreich; Wilhelm Kriz; Christian Kurts; Tammo Ostendorf; Jürgen Floege; Bart Smeets; Marcus J Moeller
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 5.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

6.  Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury.

Authors:  Jun Zou; Eishin Yaoita; Yusuke Watanabe; Yutaka Yoshida; Masaaki Nameta; Huiping Li; Zhenyun Qu; Tadashi Yamamoto
Journal:  Virchows Arch       Date:  2006-01-18       Impact factor: 4.064

7.  Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury.

Authors:  Rudolf Fuchshofer; Sabrina Ullmann; Ludwig F Zeilbeck; Matti Baumann; Benjamin Junglas; Ernst R Tamm
Journal:  Histochem Cell Biol       Date:  2011-08-04       Impact factor: 4.304

8.  Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.

Authors:  Matthew J Socha; Marlina Manhiani; Neveen Said; John D Imig; Kouros Motamed
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis.

Authors:  C Hugo; C Hugo; R Pichler; K Gordon; R Schmidt; M Amieva; W G Couser; H Furthmayr; R J Johnson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.

Authors:  R H Pichler; J A Bassuk; C Hugo; M J Reed; E Eng; K L Gordon; J Pippin; C E Alpers; W G Couser; E H Sage; R J Johnson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.